The CEO of Mylan, the company responsible for the high cost of EpiPens, is expected to speak to lawmakers Wednesday. Mylan CEO Heather Bresch said there's a "misconception about our profits" from EpiPen, according to a copy of her prepared remarks to be delivered today. The emergency allergic reaction injection treatment now costs $608 for a two-pack, up from about $100 in 2009. To fend off public outrage over the EpiPen's cost, Mylan recently raised its copay-coupon system to cover $300 of out-of-pocket costs for those with commercial insurance.